IL261548B - 7α,β11-dihydroxy-6α-ethyl-5β-cholan-24-oic acid and its use for the treatment of paranoid x receptor activated conditions - Google Patents
7α,β11-dihydroxy-6α-ethyl-5β-cholan-24-oic acid and its use for the treatment of paranoid x receptor activated conditionsInfo
- Publication number
- IL261548B IL261548B IL261548A IL26154818A IL261548B IL 261548 B IL261548 B IL 261548B IL 261548 A IL261548 A IL 261548A IL 26154818 A IL26154818 A IL 26154818A IL 261548 B IL261548 B IL 261548B
- Authority
- IL
- Israel
- Prior art keywords
- cholan
- farnesoid
- dihydroxy
- receptor
- ethyl
- Prior art date
Links
- 102100038495 Bile acid receptor Human genes 0.000 title 1
- 101000603876 Homo sapiens Bile acid receptor Proteins 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J11/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
- C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
- C07J9/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Gastroenterology & Hepatology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Steroid Compounds (AREA)
- Cephalosporin Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662306914P | 2016-03-11 | 2016-03-11 | |
| PCT/US2017/021194 WO2017156024A1 (en) | 2016-03-11 | 2017-03-07 | 3-desoxy derivative and pharmaceutical compositions thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL261548A IL261548A (en) | 2018-11-29 |
| IL261548B true IL261548B (en) | 2021-02-28 |
Family
ID=59787771
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL261548A IL261548B (en) | 2016-03-11 | 2018-09-03 | 7α,β11-dihydroxy-6α-ethyl-5β-cholan-24-oic acid and its use for the treatment of paranoid x receptor activated conditions |
Country Status (20)
| Country | Link |
|---|---|
| US (3) | US10815267B2 (https=) |
| EP (1) | EP3426348B1 (https=) |
| JP (1) | JP6892457B2 (https=) |
| KR (1) | KR102359191B1 (https=) |
| CN (1) | CN108883305B (https=) |
| AR (1) | AR107864A1 (https=) |
| AU (1) | AU2017229481B2 (https=) |
| BR (1) | BR112018068278B1 (https=) |
| CA (1) | CA3016875C (https=) |
| EA (1) | EA038632B1 (https=) |
| ES (1) | ES2874682T3 (https=) |
| IL (1) | IL261548B (https=) |
| MX (1) | MX384800B (https=) |
| PH (1) | PH12018501956A1 (https=) |
| PL (1) | PL3426348T3 (https=) |
| PT (1) | PT3426348T (https=) |
| SG (1) | SG11201807784SA (https=) |
| SI (1) | SI3426348T1 (https=) |
| TW (1) | TWI772289B (https=) |
| WO (1) | WO2017156024A1 (https=) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201703717SA (en) | 2014-11-06 | 2017-06-29 | Enanta Pharm Inc | Bile acid analogs an fxr/tgr5 agonists and methods of use thereof |
| EP3223823A4 (en) | 2014-11-26 | 2018-10-17 | Enanta Pharmaceuticals, Inc. | Bile acid analogs as fxr/tgr5 agonists and methods of use thereof |
| US10208081B2 (en) | 2014-11-26 | 2019-02-19 | Enanta Pharmaceuticals, Inc. | Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof |
| US11578097B2 (en) | 2014-11-26 | 2023-02-14 | Enanta Pharmaceuticals, Inc. | Tetrazole derivatives of bile acids as FXR/TGR5 agonists and methods of use thereof |
| EP3256134A4 (en) | 2015-02-11 | 2018-10-03 | Enanta Pharmaceuticals, Inc. | Bile acid analogs as fxr/tgr5 agonists and methods of use thereof |
| WO2016161003A1 (en) | 2015-03-31 | 2016-10-06 | Enanta Phamraceuticals, Inc. | Bile acid derivatives as fxr/tgr5 agonists and methods of use thereof |
| MA42339A1 (fr) | 2015-10-07 | 2019-01-31 | Intercept Pharmaceuticals Inc | Modulateurs du récepteur farnésoïde x |
| WO2017147159A1 (en) | 2016-02-23 | 2017-08-31 | Enanta Pharmaceuticals, Inc. | Deuterated bile acid derivatives as fxr/tgr5 agonists and methods of use thereof |
| US10323060B2 (en) | 2016-02-23 | 2019-06-18 | Enanta Pharmaceuticals, Inc. | Benzoic acid derivatives of bile acid as FXR/TGR5 agonists and methods of use thereof |
| WO2017147174A1 (en) | 2016-02-23 | 2017-08-31 | Enanta Pharmaceuticals, Inc. | Heteroaryl containing bile acid analogs as fxr/tgr5 agonists and methods of use thereof |
| ES2874682T3 (es) | 2016-03-11 | 2021-11-05 | Intercept Pharmaceuticals Inc | Derivados de 3-desoxi y composiciones farmacéuticas de los mismos |
| CN110121347A (zh) | 2016-11-29 | 2019-08-13 | 英安塔制药有限公司 | 制备磺酰脲胆汁酸衍生物的方法 |
| US10472386B2 (en) | 2017-02-14 | 2019-11-12 | Enanta Pharmaceuticals, Inc. | Bile acid derivatives as FXR agonists and methods of use thereof |
| BR112019020780A2 (pt) | 2017-04-07 | 2020-04-28 | Enanta Pharm Inc | processo para preparação de derivados de ácido biliar de carbamato de sulfonila |
| GB201812382D0 (en) | 2018-07-30 | 2018-09-12 | Nzp Uk Ltd | Compounds |
| WO2022152773A1 (en) * | 2021-01-14 | 2022-07-21 | Enyo Pharma | Method for treating chronic kidney diseases |
| WO2023288123A1 (en) | 2021-07-16 | 2023-01-19 | Interecept Pharmaceuticals, Inc. | Methods and intermediates for the preparation of 3.alpha.,7.alpha.,11.beta.-trihydroxy-6.alpha.-ethyl-5.beta.-cholan-24-oic acid |
| WO2023205447A2 (en) * | 2022-04-21 | 2023-10-26 | Intercept Pharmaceuticals, Inc. | Uses of farnesoid x receptor agonists |
| EP4611888A1 (en) * | 2022-10-31 | 2025-09-10 | Intercept Pharmaceuticals, Inc. | Uses of farnesoid x receptor agonists |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL1734970T3 (pl) * | 2004-03-12 | 2015-05-29 | Intercept Pharmaceuticals Inc | Leczenie zwłóknienia z zastosowaniem ligandów FXR |
| WO2012047495A2 (en) * | 2010-09-27 | 2012-04-12 | Kythera Biopharmaceuticals, Inc. | Methods for preparing synthetic bile acids and compositions comprising the same |
| JP6046161B2 (ja) | 2011-12-29 | 2016-12-14 | ノヴォ ノルディスク アー／エス | 非タンパク質新生アミノ酸を含むジペプチド |
| TN2015000497A1 (en) * | 2013-05-14 | 2017-04-06 | Intercept Pharmaceuticals Inc | 11-hydroxyl-derivatives of bile acids and amino acid conjugates thereof as farnesoid x receptor modulators |
| SMT202000070T1 (it) * | 2014-05-29 | 2020-03-13 | Bar Pharmaceuticals S R L | Derivati del colano per l'uso del trattamento e/o la prevenzione di malattie mediate da fxr e tgr5/gpbar1 |
| US10604544B2 (en) * | 2015-08-07 | 2020-03-31 | Intercept Pharmaceuticals, Inc. | Methods for preparation of bile acids and derivatives thereof |
| ES2874682T3 (es) | 2016-03-11 | 2021-11-05 | Intercept Pharmaceuticals Inc | Derivados de 3-desoxi y composiciones farmacéuticas de los mismos |
-
2017
- 2017-03-07 ES ES17763922T patent/ES2874682T3/es active Active
- 2017-03-07 KR KR1020187028967A patent/KR102359191B1/ko active Active
- 2017-03-07 AU AU2017229481A patent/AU2017229481B2/en active Active
- 2017-03-07 EP EP17763922.6A patent/EP3426348B1/en active Active
- 2017-03-07 WO PCT/US2017/021194 patent/WO2017156024A1/en not_active Ceased
- 2017-03-07 SI SI201730776T patent/SI3426348T1/sl unknown
- 2017-03-07 EA EA201892007A patent/EA038632B1/ru unknown
- 2017-03-07 PT PT177639226T patent/PT3426348T/pt unknown
- 2017-03-07 BR BR112018068278-0A patent/BR112018068278B1/pt active IP Right Grant
- 2017-03-07 JP JP2018547355A patent/JP6892457B2/ja active Active
- 2017-03-07 MX MX2018010983A patent/MX384800B/es unknown
- 2017-03-07 SG SG11201807784SA patent/SG11201807784SA/en unknown
- 2017-03-07 US US15/451,818 patent/US10815267B2/en active Active
- 2017-03-07 CN CN201780018432.7A patent/CN108883305B/zh active Active
- 2017-03-07 CA CA3016875A patent/CA3016875C/en active Active
- 2017-03-07 PL PL17763922T patent/PL3426348T3/pl unknown
- 2017-03-09 TW TW106107817A patent/TWI772289B/zh active
- 2017-03-13 AR ARP170100619A patent/AR107864A1/es unknown
-
2018
- 2018-09-03 IL IL261548A patent/IL261548B/en active IP Right Grant
- 2018-09-06 US US16/124,122 patent/US20190002493A1/en not_active Abandoned
- 2018-09-11 PH PH12018501956A patent/PH12018501956A1/en unknown
-
2020
- 2020-09-18 US US17/025,475 patent/US11319337B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL261548B (en) | 7α,β11-dihydroxy-6α-ethyl-5β-cholan-24-oic acid and its use for the treatment of paranoid x receptor activated conditions | |
| IL249370A0 (en) | Fap-enabled medical substances and related uses | |
| PT3973987T (pt) | Combinação compreendendo um antagonista de il-4r, um corticoesteroide e um agonista beta2-adrenérgico de ação prolongada para tratar a asma | |
| EP3307768C0 (en) | SELECTIVE PYY COMPOUNDS AND THEIR USES | |
| PL3189101T3 (pl) | Bimodalny polipropylen oraz sposób jego wytwarzania | |
| ZA201700416B (en) | Methods for treating or preventing ophthalmological conditions | |
| GB2509431B (en) | Herbicidal composition, a method for its preparation and the use thereof | |
| IL256350A (en) | Compositions and methods for the treatment of substance use disorders, addiction, and psychiatric disorders | |
| IL271728A (en) | Materials, uses and treatment methods | |
| PL3145511T3 (pl) | Kompozycja do leczenia oka | |
| PL3463214T3 (pl) | Orteza | |
| IL251616A0 (en) | Methods and compounds for the treatment and prevention of muscle loss | |
| SG11201606495QA (en) | Printing device and method for controlling the printing device | |
| IL252904A0 (en) | Methods and factors for treating diseases | |
| IL250114B (en) | Methods and compositions for the treatment of HIV-related diseases | |
| PL3492439T3 (pl) | Panel gipsowy obejmujący utwardzony korpus gipsowy, sposób wytwarzania panelu gipsowego i jego zastosowanie | |
| PT3350150T (pt) | 1,1-difeniletilenos substituídos por alcenilfenoxilo, processos para a sua preparação e sua utilização | |
| RO130539B8 (ro) | Compoziţie erbicidă, procedeu de preparare şi utilizarea acesteia | |
| PL3287647T3 (pl) | Układ zaciskowy, system osadzania wspomnianego zacisku i zastosowanie wspomnianego systemu | |
| GB2509427B (en) | Herbicidal composition, a method for its preparation and the use thereof | |
| GB2509429B (en) | Herbicidal composition, a method for its preparation and the use thereof | |
| SI3151863T1 (sl) | Hidroalkoholni sistem za nego nohtov | |
| GB2509428B (en) | Herbicidal composition, a method for its preparation and the use thereof | |
| HUE058845T2 (hu) | Nem biokonvertibilis C3-szubsztituált pregnenolon-származékok szerhasználati zavarok kezelésében történõ alkalmazásra | |
| IL247290A0 (en) | Methods of treating or preventing asthma by adding an il-4r antagonist |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FF | Patent granted | ||
| KB | Patent renewed |